XenoTherapeutics to Acquire Repare Therapeutics for $1.82 Per Share Plus CVR

Reuters11-15

XenoTherapeutics to Acquire Repare <a href="https://laohu8.com/S/LENZ">Therapeutics</a> for $1.82 Per Share Plus CVR

Repare Therapeutics Inc. has reached an agreement that will see the company become privately held, with shareholders receiving a cash payment and the opportunity to participate in future milestones and royalties from current and potential partnerships. The board of directors unanimously determined the arrangement to be in the best interests of stakeholders. The transaction is expected to close in the first quarter of 2026, after which Repare's common shares are anticipated to be delisted from the Nasdaq Global Select Market and the company will seek to cease being a reporting issuer in Canada and the United States.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repare Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251114715824) on November 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583695682?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-15 05:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583695682","market":"us","top_or_hot":-1,"title":"XenoTherapeutics to Acquire Repare Therapeutics for $1.82 Per Share Plus CVR","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      XenoTherapeutics to Acquire Repare <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for $1.82 Per Share Plus CVR\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/RPTX\">Repare Therapeutics Inc.</a> has reached an agreement that will see the company become privately held, with shareholders receiving a cash payment and the opportunity to participate in future milestones and royalties from current and potential partnerships. The board of directors unanimously determined the arrangement to be in the best interests of stakeholders. The transaction is expected to close in the first quarter of 2026, after which Repare's common shares are anticipated to be delisted from the Nasdaq Global Select Market and the company will seek to cease being a reporting issuer in Canada and the United States.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repare Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251114715824) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XenoTherapeutics to Acquire Repare Therapeutics for $1.82 Per Share Plus CVR</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXenoTherapeutics to Acquire Repare Therapeutics for $1.82 Per Share Plus CVR\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-15 05:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      XenoTherapeutics to Acquire Repare <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for $1.82 Per Share Plus CVR\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/RPTX\">Repare Therapeutics Inc.</a> has reached an agreement that will see the company become privately held, with shareholders receiving a cash payment and the opportunity to participate in future milestones and royalties from current and potential partnerships. The board of directors unanimously determined the arrangement to be in the best interests of stakeholders. The transaction is expected to close in the first quarter of 2026, after which Repare's common shares are anticipated to be delisted from the Nasdaq Global Select Market and the company will seek to cease being a reporting issuer in Canada and the United States.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repare Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251114715824) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RPTX","symbol_name":"Repare Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL5nV685:1","article_id":"2583695682","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583695682","pubTimestamp":1763156682,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Repare Therapeutics Inc. has reached an agreement that will see the company become privately held, with shareholders receiving a cash payment and the opportunity to participate in future milestones and royalties from current and potential partnerships. The board of directors unanimously determined the arrangement to be in the best interests of stakeholders. The transaction is expected to close in the first quarter of 2026, after which Repare's common shares are anticipated to be delisted from the Nasdaq Global Select Market and the company will seek to cease being a reporting issuer in Canada and the United States.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repare Therapeutics Inc. published the original content used to generate th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RPTX":"Repare Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"XenoTherapeutics将以每股1.82美元加CVR收购Repare Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RPTX":0.9},"content_text":"XenoTherapeutics to Acquire Repare Therapeutics for $1.82 Per Share Plus CVR\n    \n\nRepare Therapeutics Inc. has reached an agreement that will see the company become privately held, with shareholders receiving a cash payment and the opportunity to participate in future milestones and royalties from current and potential partnerships. The board of directors unanimously determined the arrangement to be in the best interests of stakeholders. The transaction is expected to close in the first quarter of 2026, after which Repare's common shares are anticipated to be delisted from the Nasdaq Global Select Market and the company will seek to cease being a reporting issuer in Canada and the United States.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repare Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251114715824) on November 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583695682","isCrawlerRequest":true}